Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News QuidelOrtho Corp QDEL

Technology Scientific & Technical Instruments
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies... see more

Recent & Breaking News (NDAQ:QDEL)

QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024

Business Wire 3 hours ago

NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates

GlobeNewswire 4 days ago

Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm

PR Newswire 6 days ago

QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire 13 days ago

QuidelOrtho Announces Appointment of Two Independent Directors to its Board

Business Wire December 10, 2024

QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group

Business Wire November 19, 2024

QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group

Business Wire November 19, 2024

Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm

PR Newswire November 13, 2024

QuidelOrtho Reports Third Quarter 2024 Financial Results

Business Wire November 7, 2024

QuidelOrtho to Participate in Three Upcoming Investor Conferences

Business Wire October 28, 2024

QuidelOrtho to Report Third Quarter 2024 Financial Results

Business Wire October 17, 2024

QuidelOrtho Announces New R&D Executive Leader

Business Wire October 9, 2024

QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer

Business Wire September 10, 2024

VITROS® Syphilis Assay Now Available on VITROS 3600 Immunodiagnostic System, VITROS 5600 and VITROS XT 7600 Integrated Systems in the U.S.

Business Wire August 29, 2024

QuidelOrtho to Participate in Upcoming Investor Conferences

Business Wire August 19, 2024

QuidelOrtho Reports Second Quarter 2024 Financial Results

Business Wire July 31, 2024

Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600

PR Newswire July 23, 2024

QuidelOrtho to Report Second Quarter 2024 Financial Results

Business Wire July 17, 2024

Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX), Akero Therapeutics, Inc. (NASDAQ: AKRO), Rivian Automotive, Inc. (NASDAQ: RIVN), and QuidelOrtho Corporation (NASDAQ: QDEL)

Accesswire June 27, 2024

Lifshitz Law PLLC Announces Investigations of QuidelOrtho Corporation (NASDAQ: QDEL), Ocugen Inc. (NASDAQ: OCGN), Sonder Holdings, Inc. (NASDAQ: SOND), and Humana, Inc. (NYSE: HUM)

Accesswire June 12, 2024